Colorectal cancer is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related death. Despite decades of research and a growing arsenal of targeted therapies, advanced-stage colorectal cancer remains difficult to treat, and resistance to standard chemotherapy continues to be a major clinical challenge.
At the center of nearly every laboratory study into colon cancer biology, drug response, and resistance mechanisms sits a cell line. These human colon cancer cell lines are the foundation of preclinical research, and the quality of the science depends heavily on choosing the right model for the right question.
This guide covers the most widely used human colon cancer cell lines, what each one models, how they differ genetically and biologically, and how researchers decide which line to use for a given experiment.
Why Colon Cancer Cell Lines Matter
Colorectal cancer is not a genetically uniform disease. Different tumors carry different combinations of mutations, affecting signaling pathways like WNT, KRAS, BRAF, and PI3K. Some tumors are microsatellite instable, meaning their DNA mismatch repair system is defective, while others are microsatellite stable. These distinctions have major consequences for how a tumor responds to chemotherapy, targeted therapy, and immunotherapy.
No single cell line captures all of this diversity. Researchers working in colorectal cancer drug discovery need a panel of well-characterized lines that together represent the spectrum of molecular subtypes seen in patients. Understanding the genetic background and biological behavior of each line is what allows researchers to design experiments that are both scientifically rigorous and clinically meaningful.
HCT116: The Gold Standard for Colon Cancer Research
HCT116 is one of the most widely used colon cancer cell lines in the world. It was derived from the colon of a 48 year old male patient diagnosed with colorectal carcinoma and has become a go-to model across a remarkable range of research applications, from basic signaling studies to high-throughput drug screening.
Key Genetic Features
The defining mutation in HCT116 is a KRAS G13D mutation, a single amino acid change in codon 13 of the KRAS proto-oncogene. This mutation locks the KRAS protein in a constitutively active state, driving continuous proliferation through the RAS/RAF/MEK/ERK signaling pathway. This is clinically relevant because KRAS mutations are present in around 40 to 45 percent of all colorectal cancer patients and predict resistance to anti-EGFR therapies like cetuximab and panitumumab.
HCT116 cells carry wild-type TP53, which distinguishes them from many other colon cancer lines and makes them particularly useful for studying p53-dependent drug responses and apoptosis pathways. The cell line is also microsatellite instable due to a deficiency in the MLH1 mismatch repair gene, which classifies it as an MSI-H tumor model.
Biological Characteristics
HCT116 cells display an epithelial-like morphology and grow as adherent monolayers under standard conditions. Their doubling time is approximately 20 to 24 hours, making them fast-growing and practical for experiments requiring large cell numbers in a short time. Around 70 percent of HCT116 cells show consistent genetic profiles within the culture, giving researchers a relatively homogeneous cell population.
HCT116 cells form spheroids when cultured under non-adherent conditions, producing structures typically 150 to 400 micrometers in diameter. This capacity for 3D growth makes them useful for tumor spheroid assays, which better model the hypoxic core and drug penetration challenges of solid tumors. They are also tumorigenic in mouse xenograft models, forming subcutaneous tumors reliably in immunodeficient mice.
Research Applications
HCT116 is used across a wide range of research areas including cell cycle analysis, apoptosis assays, CRISPR-based gene editing studies, chemotherapy screening, and pathway inhibitor evaluation. Several isogenic derivative lines have been generated from HCT116, including HCT116 p53 knockout cells, which allow direct comparison of p53-dependent and p53-independent responses to the same treatment conditions.
HT-29: Modeling Drug Resistance and Differentiation
HT-29 is another foundational colon cancer cell line, established from the primary tumor of a 44 year old female patient with colorectal adenocarcinoma. It is included in the NCI-60 cell line panel and has been used in thousands of published studies.
Key Genetic Features
Unlike HCT116, HT-29 carries mutant TP53, along with a BRAF V600E mutation, the same mutation targeted by BRAF inhibitors like vemurafenib in melanoma treatment. It also carries a PIK3CA mutation, which activates the PI3K/AKT signaling pathway. HT-29 is microsatellite stable, making it representative of the majority of colorectal cancers seen in clinical practice, which are MSS rather than MSI-H.
Biological Characteristics
HT-29 cells grow more slowly than HCT116, with a doubling time of approximately 20 to 24 hours under optimal conditions, though some sources report longer doubling times depending on culture conditions. What distinguishes HT-29 is its capacity for differentiation. Under certain conditions, HT-29 cells can differentiate into goblet-like cells or absorptive cells, making them a useful model for studying intestinal epithelial differentiation alongside cancer biology.
HT-29 cells are commonly used in studies of mucin production, colonosphere formation, and intestinal barrier function. They are also one of the standard models for studying multidrug resistance, particularly resistance to 5-fluorouracil, which is the backbone of standard colorectal cancer chemotherapy.
Research Applications
HT-29 is particularly valuable in drug discovery and screening studies focused on BRAF and PI3K pathway inhibitors, and in comparative studies alongside KRAS-mutant lines like HCT116 and SW480. The genetic contrast between the BRAF-mutant, MSS profile of HT-29 and the KRAS-mutant, MSI-H profile of HCT116 makes them a complementary pair that together cover a broader range of colorectal cancer molecular subtypes.
SW480 and SW620: A Paired Model of Primary Tumor and Metastasis
SW480 and SW620 are among the most biologically interesting cell lines in colorectal cancer research because they represent something rare: two lines derived from the same patient at different stages of disease. SW480 was established from the primary colon tumor, and SW620 was established from a lymph node metastasis obtained one year later from the same individual.
Key Genetic Features
Both SW480 and SW620 carry identical KRAS G12V mutations and mutant TP53. Despite sharing the same mutation profile, the two lines show significant epigenetic differences that reflect the changes that occurred during the progression from primary tumor to metastatic disease. These epigenetic differences affect gene expression patterns related to invasion, adhesion, and epithelial-to-mesenchymal transition.
Research Applications
The SW480/SW620 pair is used to study the molecular events that drive metastatic progression in colorectal cancer. By comparing the two lines directly, researchers can identify changes in gene expression, protein function, and drug sensitivity that are specifically associated with the transition to a metastatic phenotype. This paired design is one of the most powerful tools available for metastasis research because it controls for patient-specific genetic background.
SW480 cells are generally less aggressive and more epithelial in character, while SW620 cells show more mesenchymal features and greater invasive potential. SW480 is also one of the standard lines used to study WNT signaling pathway activity in colorectal cancer.
Caco-2: The Intestinal Absorption Model
Caco-2 is a human colorectal adenocarcinoma cell line that occupies a unique position in biomedical research. Unlike most colon cancer lines used primarily for oncology research, Caco-2 is used most widely as a model of intestinal absorption and drug permeability. When cultured to confluence on permeable membrane inserts, Caco-2 cells spontaneously differentiate into a monolayer resembling small intestinal epithelium, complete with tight junctions, brush border enzymes, and transport proteins.
This property makes Caco-2 a standard tool in pharmaceutical development for predicting oral drug absorption and bioavailability. It is also used in studies of intestinal drug transport mechanisms, toxicology, and the effects of food components on intestinal barrier function.
DLD-1: An MSI-H Model with Clinical Relevance
DLD-1 is a colorectal cancer cell line that is genetically related to HCT-15. Both lines were established from the same patient and carry identical genetic profiles, though they have been maintained separately in different laboratories and show some phenotypic differences. DLD-1 carries a KRAS G13D mutation, the same as HCT116, and is microsatellite instable due to MLH1 deficiency.
DLD-1 is commonly used in drug resistance studies and in comparative analyses with HCT116 because the two lines share key mutations but have different experimental histories. It is also used in studies of immunotherapy response, as MSI-H tumors are known to respond better to immune checkpoint inhibitors than MSS tumors.
LoVo: A Model for Studying Metastatic and Drug-Resistant Disease
LoVo was derived from a metastatic colorectal cancer deposit in the left supraclavicular region of a 56 year old male patient. It carries a mutant KRAS gene and wild-type TP53 and is microsatellite instable. LoVo cells grow more slowly than HCT116 or HT-29 and have a doubling time of approximately 40 to 48 hours.
LoVo is used in studies of drug resistance, particularly to anthracyclines and fluorouracil. Resistant sublines have been developed from LoVo, making it a useful model for studying acquired resistance mechanisms in a metastatic disease context.
MC38: The Mouse Colon Cancer Line for Immunotherapy Research
MC38 is a murine colon cancer cell line derived from a C57BL/6 mouse and is one of the most important models for colorectal cancer immunotherapy research. Unlike human cell lines, which require immunodeficient mice for xenograft studies, MC38 cells grow readily in immunocompetent syngeneic C57BL/6 mice, allowing researchers to study the full tumor immune microenvironment including T cells, natural killer cells, and macrophages.
MC38 tumors are known to be immunogenic and responsive to immune checkpoint inhibitors, particularly anti-PD-1 and anti-PD-L1 antibodies. This makes MC38 one of the standard preclinical models for evaluating new immunotherapy approaches and combination strategies before moving into clinical trials. The line is also used to study the role of the tumor microenvironment in colorectal cancer progression and immune evasion.
How to Choose the Right Colon Cancer Cell Line
With so many available lines, choosing the right model depends on the specific question being asked.
Mutation Status
If the goal is to study KRAS-mutant biology or evaluate drugs in a KRAS-mutant background, HCT116, SW480, or DLD-1 are appropriate. For BRAF-mutant research, HT-29 is the standard choice. For wild-type RAS studies, lines like Caco-2 or specific isogenic derivatives are used.
Microsatellite Status
MSI-H lines such as HCT116 and DLD-1 are used for mismatch repair deficiency research and for studying immunotherapy sensitivity. MSS lines like HT-29 and SW480 represent the majority of clinical colorectal cancers and are more relevant for conventional chemotherapy and targeted therapy studies.
Metastasis Research
The SW480/SW620 paired system is the best available tool for directly comparing primary tumor and metastatic biology in a controlled genetic background. LoVo provides a model for studying metastatic disease in a single-line context.
Immunotherapy Research
For studies requiring an intact immune system, MC38 in syngeneic C57BL/6 mice is the standard preclinical model. Human cell line xenograft studies in immunodeficient mice cannot evaluate immunotherapy mechanisms, making MC38 essential for this class of experiments.
Researchers who need a broad view of drug activity across multiple colorectal cancer subtypes often use a panel approach, testing compounds across three to five lines with different mutation profiles simultaneously. AstralCell provides a range of authenticated colon cancer cell lines including the major models described in this guide, with in-house quality control and STR-verified identity.
The Role of Authentication in Colon Cancer Research
Several colon cancer cell lines have documented histories of cross-contamination or mislabeling. HT-29 and HCT116 are among the lines where authentication issues have been reported in the published literature. Given the importance of mutation status in colorectal cancer research, working with an incorrectly identified line can completely invalidate experimental conclusions. All colon cancer cell lines should be authenticated by STR profiling before use, and researchers should source their cells from suppliers with documented quality control practices. You can read more about why authentication matters and how it works in our guide on cell line authentication and STR profiling.
Frequently Asked Questions
What is the most commonly used colon cancer cell line?
HCT116 is widely regarded as the most commonly used colon cancer cell line in research. It carries a KRAS G13D mutation, wild-type TP53, and is microsatellite instable, making it relevant for a broad range of oncology and drug discovery studies.
What is the difference between HCT116 and HT-29?
HCT116 carries a KRAS mutation and is microsatellite instable with wild-type TP53. HT-29 carries a BRAF V600E mutation, mutant TP53, and is microsatellite stable. Together they represent two distinct molecular subtypes of colorectal cancer and are often used as a complementary pair in drug screening studies.
What are SW480 and SW620 used for?
SW480 and SW620 are derived from the same patient at different disease stages. SW480 represents the primary tumor and SW620 the lymph node metastasis. They are used together to study the molecular changes associated with metastatic progression in colorectal cancer.
What makes MC38 different from human colon cancer cell lines?
MC38 is a mouse colon cancer cell line that grows in immunocompetent syngeneic mice. This allows researchers to study the tumor immune microenvironment and evaluate immunotherapy approaches, which cannot be done using human cell lines in immunodeficient xenograft models.
What culture medium does HCT116 use?
HCT116 cells are typically cultured in McCoy's 5A medium supplemented with 10 percent fetal bovine serum. The medium is generally changed every two to three days, and cells are passaged at around 80 to 90 percent confluence.
Is HT-29 sensitive to 5-fluorouracil?
HT-29 is one of the standard models used to study 5-fluorouracil resistance in colorectal cancer research. While the parental line shows some sensitivity, resistant sublines have been derived from HT-29 to model acquired resistance to this chemotherapy backbone drug.
Do colon cancer cell lines need to be authenticated?
Yes. Several widely used colon cancer cell lines have documented authentication issues. Given that mutation status directly affects drug response in colorectal cancer research, using an incorrectly identified line can fundamentally compromise experimental conclusions. STR profiling authentication is required by most major journals before publication.